Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

The investable message is less about “healthcare vs biotech” than about factor exposure: XLV is a quality/defensive proxy with meaningful concentration in a few mega-cap winners, while FBT is a higher-beta venture-capital basket disguised as an ETF. That means the near-term risk/reward is driven less by sector direction than by whether the market continues to pay for earnings durability and cash-generation versus binary pipeline optionality. In a risk-off tape, XLV should attract incremental institutional ballast; in a risk-on melt-up, FBT can still outperform, but only if small/mid-cap biotech financing conditions stay benign.

Second-order, XLV is becoming increasingly dependent on LLY as a portfolio-level “single-name macro,” which creates hidden concentration risk inside what many investors treat as a diversified defensive sleeve. If GLP-1 execution or pricing sentiment wobbles, the ETF can de-rate even if the broader healthcare complex is stable. By contrast, FBT’s equal-weight structure amplifies idiosyncratic clinical catalysts, but it also leaves holders exposed to dilution and follow-on risk if capital markets tighten over the next 1-3 months.

The contrarian read is that the fee spread is real but not the main driver: for short-horizon investors, volatility and concentration matter more than expense ratio. The consensus may be overestimating FBT’s “growth” purity and underestimating how much of its upside depends on continued speculative appetite. Over 6-18 months, the cleaner trade may be to own the lower-vol healthcare compounders and avoid paying up for biotech beta unless you have a specific catalyst map.